Hainan Shuangcheng Pharmaceut (SHE:002693) — Market Cap & Net Worth
Market Cap & Net Worth: Hainan Shuangcheng Pharmaceut (002693)
Hainan Shuangcheng Pharmaceut (SHE:002693) has a market capitalization of $559.49 Million (CN¥3.82 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11767 globally and #3368 in its home market, demonstrating a 7.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Shuangcheng Pharmaceut's stock price CN¥9.22 by its total outstanding shares 414689750 (414.69 Million). Also see Hainan Shuangcheng Pharmaceut balance sheet assets for a full breakdown of the balance sheet.
Hainan Shuangcheng Pharmaceut Market Cap History: 2015 to 2026
Hainan Shuangcheng Pharmaceut's market capitalization history from 2015 to 2026. Data shows change from $901.13 Million to $559.49 Million (-1.80% CAGR). Also see Hainan Shuangcheng Pharmaceut cash conversion from operations for how efficiently the company converts equity into cash flow.
Hainan Shuangcheng Pharmaceut Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Shuangcheng Pharmaceut's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Hainan Shuangcheng Pharmaceut share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.53x
Hainan Shuangcheng Pharmaceut's market cap is 1.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.18x
Hainan Shuangcheng Pharmaceut's market cap is 22.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $654.15 Million | $145.14 Million | -$388.41 Million | 4.51x | N/A |
| 2017 | $386.55 Million | $246.77 Million | $6.31 Million | 1.57x | 61.21x |
| 2018 | $236.05 Million | $337.24 Million | -$69.46 Million | 0.70x | N/A |
| 2019 | $282.78 Million | $346.65 Million | $24.66 Million | 0.82x | 11.47x |
| 2020 | $262.75 Million | $269.44 Million | -$53.33 Million | 0.98x | N/A |
| 2021 | $286.42 Million | $320.29 Million | -$20.33 Million | 0.89x | N/A |
| 2022 | $441.16 Million | $274.75 Million | $9.01 Million | 1.61x | 48.95x |
| 2023 | $455.72 Million | $235.93 Million | -$50.74 Million | 1.93x | N/A |
| 2024 | $1.11 Billion | $174.21 Million | -$78.30 Million | 6.38x | N/A |
| 2025 | $422.35 Million | $276.76 Million | $19.04 Million | 1.53x | 22.18x |
Competitor Companies of 002693 by Market Capitalization
Companies near Hainan Shuangcheng Pharmaceut in the global market cap rankings as of September 19, 2026. Review 002693 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hainan Shuangcheng Pharmaceut by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Hainan Shuangcheng Pharmaceut Historical Marketcap From 2015 to 2026
Between 2015 and today, Hainan Shuangcheng Pharmaceut's market cap moved from $901.13 Million to $ 559.49 Million, with a yearly change of -1.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥559.49 Million | +32.47% |
| 2025 | CN¥422.35 Million | -62.03% |
| 2024 | CN¥1.11 Billion | +144.07% |
| 2023 | CN¥455.72 Million | +3.30% |
| 2022 | CN¥441.16 Million | +54.03% |
| 2021 | CN¥286.42 Million | +9.01% |
| 2020 | CN¥262.75 Million | -7.08% |
| 2019 | CN¥282.78 Million | +19.79% |
| 2018 | CN¥236.05 Million | -38.93% |
| 2017 | CN¥386.55 Million | -40.91% |
| 2016 | CN¥654.15 Million | -27.41% |
| 2015 | CN¥901.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Hainan Shuangcheng Pharmaceut was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $559.49 Million USD |
| MoneyControl | $559.49 Million USD |
| MarketWatch | $559.49 Million USD |
| marketcap.company | $559.49 Million USD |
| Reuters | $559.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more